The CSC-targeting therapy via mTOR inhibition has shown enhanced anti-cancer efficacy, offering hope for addressing existing limitations in cancer treatment, such as drug resistance caused by the active CSCs (Fig. 5) [159, 184, 317–319]. Here, MTOR is linked to cancer.